Alivus Life Sciences Limited — Q3 FY26
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crore, up 4.8% YoY, driven by a strong CDMO recovery (85.3% YoY growth) and robust non-GPL business grow...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
82%Questions answered1Evaded / deflected11Questions auditedContradictedNumbers vs filing
Answered
High priority
What has changed to sustain margins despite R&D and PLI headwinds?
Asked by Pratik Kotari, Munich PMS
Management clearly listed three drivers: CDMO, new launches, and operational efficiency.
Read the exchange
Question
despite KI going away, despite R&D spend ramping up, we still have been able to maintain margins and now we are highlighting that we'll be able to even go beyond that. So this margin differential... can you just highlight what has changed in terms of our business?
Dr. Ravi (CEO)
CDMO has begun to contribute more. There's also launches that are happening across markets and usually newer products tend to get us much higher margins. Plus on the operational side we've performed a lot better in terms of raw material costs and on the operation side. All this put together is sustainable.
Partial answer
High priority
Why is Shapur capacity lower and delayed vs earlier guidance?
Asked by Pratik Kotari, Munich PMS
Management admitted delay and capacity reduction but attributed to calibration without quantifying impact.
capacity reduction acknowledged but not fully explainedblamed calibration
Read the exchange
Question
Shapur it seems the capacity that we had planned or guided earlier it seems to be much lower... what has changed how is it different from what we had said earlier to now?
Dr. Ravi (CEO)
Shapur is a little delayed, it's not going to impact business because more than 80% of our business comes from the reg markets. Shapur is delayed by like 3 months, so we expect Shapur to start operations by July. The capacity is calibrated; we've done product mapping to ensure utilization.
Answered
High priority
Can you break down the margin improvement levers more granularly?
Asked by Ahmed Madha, Unified Capital
Management provided specific details on each lever and their contribution.
Read the exchange
Question
Can you elaborate or explain little granularly... you have mentioned three levers. One is new launches, second is CDMO business, third efficiency. If you can break it up and explain a little bit better how they explain the margin improvement in current quarter and your overall guidance.
Dr. Ravi (CEO)
Operational efficiency impacts margins across the board. Launches contribute much higher margin, especially in Europe, China, Latam, Russia. CDMO: project 4 and 5 kicked in H2, volume pickup significant. This sustainability gives confidence to reach those margin levels.
Answered
High priority
Does capacity delay risk next year's growth?
Asked by Ahmed Madha, Unified Capital
Management gave clear capacity timeline and growth guidance.
Read the exchange
Question
With the little bit of delay, little bit of capacity fine-tuning, does that sort of risk our growth for next year or will we have enough capacity to deliver decent growth?
Dr. Ravi (CEO)
Capacity is no longer a limitation. Brownfield expansions at Ankleshwar will be operational in Q2 next year, giving runway for at least two years for reg markets. Shapur can free up capacity by moving RO products. We guide to high single-digit growth next year with margins in 30-32% range.
Answered
Medium priority
Any new CDMO projects beyond the current five?
Asked by Ahmed Madha, Unified Capital
Management gave a clear timeline and number of expected new projects.
Read the exchange
Question
The number of projects that we have, is there any more visibility for new projects getting added? Any conversations are at the second of sort of conclusion or will the project addition be gradual from here on beyond the five?
Dr. Ravi (CEO)
Good traction on CDMO. Hopefully we'll conclude one or two projects by the middle of the calendar year, first quarter we should conclude. We have even supplied some early quantities. I'm confident by Q1 next year we will have brought in one or maybe two projects more.
Evasive
Medium priority
Why not be more aggressive with organic or inorganic growth given cash?
Asked by Yogi, Omega Portfolio Advisor
Management acknowledged the question but gave no concrete plans or targets.
no specific plansvague on timingdefensive about conservatism
Read the exchange
Question
Why is there any reason we aren't willing to be more aggressive either with our organic expansion or our inorganic expansion?
Dr. Ravi (CEO)
Organic is pretty well scripted. Inorganic, we are looking out. When the right opportunity comes along we will take the right steps. We are not going to do things willy-nilly; it's hard-earned money and we'll deploy it well.
Partial answer
Low priority
What portion of manufacturing will use flow chemistry?
Asked by Krishna Indu Saha, Quantum Asset Management
Management gave examples but did not quantify the portion of manufacturing impacted.
no percentage givenonly qualitative examples
Read the exchange
Question
When you speak about implementing flow chemistry, are we going to implement it all across? What percentage or what portion of our total manufacturing in flow chemistry so we could generate more cost savings?
Dr. Ravi (CEO)
We are targeting the bigger volume APIs. Not everything is amenable to flow. Where you have long reaction time, lot of energy consumption, excessive reagents, there flow can have a big impact. We had a successful product where we brought down cost to 40% of what it was.
Answered
High priority
Why only high single-digit revenue growth despite 50% capacity increase?
Asked by Karthik Swami Natan, Kataran
Management explained the capacity allocation and the impact of price erosion on revenue growth.
Read the exchange
Question
You're going from 1,400 kl to 2,100 kl, almost a 50% increase in reactor capacity. But when you're talking about revenue growth, you're only talking about high single-digit growth. Why such a large difference?
Dr. Ravi (CEO)
400 kl is just backward integration to protect larger molecules and margins. The remaining is for growth. There is price erosion, so volume growth is much higher than revenue growth. We've been operating at 90% capacity, which is risky; we need surge capacity.
Answered
Medium priority
What is the peak revenue potential of current CDMO contracts?
Asked by Nitina Garval, Dan Capital
Management provided specific revenue estimates for the CDMO projects.
Read the exchange
Question
On the CDMO business, the contracts we have right now, what should be the peak sort of annual potential or revenue potential for those contracts at peak?
Dr. Ravi (CEO)
Project 4 and 5 together would get us around $12 million, could be a little higher. Earlier three projects run rate around 140 crores. So we expect to be in a reasonably good place with these five projects.
Partial answer
Medium priority
Why not target larger CDMO deals like other Indian CDMOs?
Asked by Sajal Kapoor, antifragile thinking
Management explained constraints but did not address the core ask of scaling up deal sizes.
defended current strategyno commitment to changedismissed comparison
Read the exchange
Question
Why can't we aim for higher magnitude and faster growth in CDMO? Because our scientific talent is also right up there.
Dr. Ravi (CEO)
How many such $50-100 million opportunities are there? Not many. Big pharma keeps patented products in Ireland due to tax rates. We are targeting lifecycle management for specialty companies. We are getting projects on board within 18-24 months. We are likely to get to seven projects in another half year.
Answered
High priority
What is the volume vs price growth breakdown for next year?
Asked by Ankit Manocha, Arezi Ventures Family Office
Management gave explicit numbers for price erosion and implied volume growth.
Read the exchange
Question
When you say single digit high single digit revenue growth for next year, do you build in any base cases for what is the volume and what is the pricing break up?
Dr. Ravi (CEO)
We are factoring in 5% pricing price erosion. With high single-digit growth, we should be geared up for about 15% to 17% volume growth.
Answered
Medium priority
What will be capacity utilization and margin profile after expansion?
Asked by Ankit Manocha, Arezi Ventures Family Office
Management provided specific utilization range and margin impact assessment.
Read the exchange
Question
After you complete your capacity expansion, what would be the margin profile that you're looking at for the business and what are the capacity utilization levels for FY27?
Dr. Ravi (CEO)
Capacity utilization should be between 85 and 90 when new capacity comes online. 400 kl is for backward integration, remaining for regular CDMO and API. We will operate at around 85%. Under absorption is not going to significantly hit our EBITDA.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Revenue growth guidance high single-digit next year | 8% | 4.8% | Overstated vs filing |
| EBITDA margin guidance 30-32% range | 31% | 36.4% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.